source
- ICER finds AstraZeneca’s blood pressure pill Baxfendy not cost-effective at $10,950 a yearICER released a report saying the clinical benefits of AstraZeneca’s new blood pressure medication Baxfendy do not justify its listed price. The agency noted the drug is priced at $10,950 per pati…
- Overseas MDMA and psilocybin makers eye U.S. market as regulatory landscape easesCompanies that produce MDMA and psilocybin for patients abroad are turning their attention to the United States, hoping to leverage experience gained under more permissive foreign rules. Rising pol…